Corcept (CORT) Upgraded to Strong Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Vertex Pharmaceuticals (VRTX) Receives a Buy from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher?
Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...
bovnews18h
Corcept Therapeutics Incorporated (CORT)’s Stock Surge: What You Need to Know
On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...
New Strong Buy Stocks for November 5th
List today: American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus ...